An interventional study of Antihypertensive drugs (no restriction on the type of drugs) in Stroke Patients, sponsored by Xijing Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-12-29.
Sponsored by Xijing Hospital · Not applicable, Interventional, and Prevention
Ischemic stroke accounts for 80% of all strokes and there is a lack of effective treatment options.Mechanical thrombectomy can significantly improve the vascular recanalization rate and reduce the disability rate of stroke, but the problem of reperfusion injury caused by vascular recanalization is more prominent than before.
The most common manifestation of reperfusion injury is postoperative hemorrhage transformation in the infarct area, which is caused by the inability of blood vessels to tolerate normal perfusion pressure after endothelial cell injury.Therefore, in addition to using necessary strategies to reduce the risk of bleeding before and during surgery, maintaining an appropriate and individualized perfusion pressure after surgery is also an important strategy to prevent and treat postoperative bleeding.
Lead a multicenter, randomized, controlled study looking at Individuation lowers blood pressure.( Drop systolic blood pressure to 90-110mmHg，Blood pressure not lower than 90/60 mm Hg，The reduced blood pressure was maintained for 48 hours). Influence of the incidence of hemorrhage transformation caused by reperfusion injury after mechanical thrombectomy and prognosis (modified Rankin Scale (mRS) score and proportion of patients with mRS≤2) at 48hours, 14 and 90 days after surgery.Thus, provide clinical evidence for blood pressure management strategy after mechanical thrombectomy.
7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.
This study's planned enrollment of 120 is above the median of 50 across 5,369 interventional studies indexed under Stroke.
Browse Stroke studies →Xijing Hospital is the lead sponsor of 465 studies on the registry; 157 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
1. Lower systolic blood pressure to 90-110 mm Hg. 2. Blood pressure not lower than 90/60 mm Hg 3. Hypotensive maintenance treatment for 48 hours.
Drug: Antihypertensive drugs (no restriction on the type of drugs)
1. Subjects with basic blood pressure(BBP) \> 140/90 mm Hg should have BBP lowered to about 140/90 mm Hg. 2. Subjects whose BBP was less than 140/90mm Hg were kept BBP.
Drug: Antihypertensive drugs (no restriction on the type of drugs)
The division of care unit doctors and nurses is clear, the former is responsible for giving medical advice, the latter is responsible for carrying it out. The experimental group and the control group were given intravenous antihypertensive drugs (no restriction on the type of drugs), and their blood pressure reached the standard within 2 hours after vascular opening.
Modified Rankin Scale score
Good prognosis rate (mRS ≤ 2 points) at 90 days after surgery in the test and control groups. Modified Rankin Scale scores range from 0 to 6, with a lower score indicating a better prognosis .
Time frame: 90 days
The incidence of symptomatic bleeding transformation
The secondary outcome was the incidence of symptomatic bleeding transformation due to reperfusion injury within 48 hours after surgery.
Time frame: 48 hours
National Institution of Health Stroke Scale scores
NIHSS scores at 48 hours postoperatively in the test group and the control group. NIHSS scores range from 0-42, the higher the score the more severe the patient's clinical symptoms
Time frame: 48 hours
Modified Rankin Scale score
The mRS scores at 14 days after surgery in the test and control groups. Modified Rankin Scale scores range from 0 to 6, with a lower score indicating a better prognosis .
Time frame: 14 days
This study is status unknown, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xijing Hospital